Literature DB >> 15373778

BRAF kinase gene V599E mutation in growing melanocytic lesions.

Robert Loewe1, Harald Kittler, Gottfried Fischer, Ingrid Faé, Klaus Wolff, Peter Petzelbauer.   

Abstract

Mutations in the BRAF-gene are found in benign and malignant melanocytic lesions, >90% being a V599E mutation. This mutation results in constitutively active kinase function and increased colony formation in vitro. The biological impact of this mutation in vivo is still debated. To address this question, we used our digital epiluminescence image archive and retrospectively selected 49 melanocytic lesions, which did not meet the criteria of melanoma at the initial presentation. Mean 12 months later these lesions were excised because of increased size or changed structure and BRAF(V599E) mutations were analyzed. Among 36 growing lesions, BRAF(V599E) mutations were found in 16 (11 melanomas and 5 nevi). Among 13 lesions with structural changes, BRAF(V599E) mutations were found in 4 (3 melanomas and 1 nevus). Thirty-five randomly selected additional lesions with no changes during follow-up served as controls, all nevi by histology, and two of them showed a BRAF(V599E) mutation. Statistics revealed odds for the presence of the BRAF(V599E) mutation being seven times higher in lesions with structural changes and 13 times higher in growing lesions as compared with lesions without changes. This raises the question if the V599E mutation determines lesions at risk developing into melanoma and if not, what are the mechanisms controlling growth stop in benign lesions?

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15373778     DOI: 10.1111/j.0022-202X.2004.23402.x

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  8 in total

Review 1.  Cutaneous toxicities of new treatments for melanoma.

Authors:  A Boada; C Carrera; S Segura; H Collgros; P Pasquali; D Bodet; S Puig; J Malvehy
Journal:  Clin Transl Oncol       Date:  2018-05-24       Impact factor: 3.405

Review 2.  Biologically distinct subsets of nevi.

Authors:  Tova Rogers; Maria L Marino; Patricia Raciti; Manu Jain; Klaus J Busam; Michael A Marchetti; Ashfaq A Marghoob
Journal:  G Ital Dermatol Venereol       Date:  2016-04-27       Impact factor: 2.011

3.  NRAS and BRAF mutations in melanoma-associated nevi and uninvolved nevi.

Authors:  Philipp Tschandl; Anna Sophie Berghoff; Matthias Preusser; Sebastian Burgstaller-Muehlbacher; Hubert Pehamberger; Ichiro Okamoto; Harald Kittler
Journal:  PLoS One       Date:  2013-07-08       Impact factor: 3.240

4.  Human nevi lack distinguishing senescence traits.

Authors:  Sieu Tran; Helen Rizos
Journal:  Aging (Albany NY)       Date:  2013-02       Impact factor: 5.682

5.  PRMT5 is upregulated in malignant and metastatic melanoma and regulates expression of MITF and p27(Kip1.).

Authors:  Courtney Nicholas; Jennifer Yang; Sara B Peters; Matthew A Bill; Robert A Baiocchi; Fengting Yan; Saïd Sïf; Sookil Tae; Eugenio Gaudio; Xin Wu; Michael R Grever; Gregory S Young; Gregory B Lesinski
Journal:  PLoS One       Date:  2013-09-30       Impact factor: 3.240

6.  Targeted BRAF inhibition impacts survival in melanoma patients with high levels of Wnt/β-catenin signaling.

Authors:  Andy J Chien; Lauren E Haydu; Travis L Biechele; Rima M Kulikauskas; Helen Rizos; Richard F Kefford; Richard A Scolyer; Randall T Moon; Georgina V Long
Journal:  PLoS One       Date:  2014-04-14       Impact factor: 3.240

7.  BRAF, NRAS, and GNAQ Mutations in Conjunctival Melanocytic Nevi.

Authors:  Jasmine H Francis; Hans E Grossniklaus; Larissa A Habib; Brian Marr; David H Abramson; Klaus J Busam
Journal:  Invest Ophthalmol Vis Sci       Date:  2018-01-01       Impact factor: 4.799

8.  Growth-Curve Modeling of Nevi With a Peripheral Globular Pattern.

Authors:  Shirin Bajaj; Stephen W Dusza; Michael A Marchetti; Xinyuan Wu; Maira Fonseca; Kivanc Kose; Johanna Brito; Cristina Carrera; Vanessa P Martins de Silva; Josep Malvehy; Susana Puig; Sarah Yagerman; Tracey N Liebman; Alon Scope; Allan C Halpern; Ashfaq A Marghoob
Journal:  JAMA Dermatol       Date:  2015-12-01       Impact factor: 10.282

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.